Keywords: Tumors (Pre-Treatment), Brain
Motivation: IDH-mutant diffuse adult type gliomas almost invariably lead to fatality. The INDIGO trial found vorasidenib significantly improving progression-free survival in non-contrast enhancing IDH mutant CNS grade 2 glioma patients.
Goal(s): The purpose of this study was to non-invasively predict both contrast enhancement and IDH mutation in glioma patients.
Approach: We employed a machine learning approach on 7T MRSI data to forecast IDH mutation status and contrast-enhancing tumor tissue in adult diffuse gliomas.
Results: Our models performed well in the training and the testing set (AUC ≥ 0.8) for both, IDH mutation and contrast enhancement prediction.
Impact: With regard to emerging IDH inhibition therapies in IDH mutant non-contrast enhancing diffuse gliomas, non-invasive prediction of IDH mutation status and contrast enhancement are of utmost importance for glioma patients. 7T MRSI can be successfully applied to this task.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords